Thoracic oncologist Dr Joshua Sabari is joining us from WCLC 2026 in Seoul to report on the latest data and share his expert perspectives on the most recent advances in HER2-mutant non-small cell lung cancer (NSCLC).
Dr Sabari is expected to share insights on the following studies:
- DESTINY-Lung04: First-line trastuzumab deruxtecan in patients with metastatic HER2-mutant NSCLC (Primary Results)
Rotow J, et al. PL03.08, WCLC 2026 - SOHO-01: Molecular landscape of acquired resistance to sevabertinib in HER2-mutant NSCLC (Exploratory Biomarker Analysis)
Le X, et al. MO12.04, WCLC 2026 - Beamion LUNG-1: Acquired resistance to zongertinib treatment in patients with HER2-mutant NSCLC (Phase 1b Study)
Planchard D, et al. MO12.05, WCLC 2026
Will new data impact clinical practice? Come back soon to find out.
See more lung cancer data from recent conferences: Catch up on Highlights from ASCO 2026 and Oncogene-addicted NSCLC highlights from ELCC 2026 on the right of this page, or scroll up to 'Summary and next episodes' if you're on mobile.

Downloadable
4 MIN
Aug 2026
